Quantitative histomorphometry and quantitative polymerase chain reaction (PCR) as assessment tools for product development

Robert G. Audet, Robert B. Diller, Robert S Kellar

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

In the current chapter, 12 normal, healthy subjects were enrolled in a clinical study to assess the efficacy of a topically delivered therapeutic to improve the health and appearance of skin. Clinical and histological assessments along with immunohistochemistry and gene expression results were evaluated using quantitative methods for a comprehensive determination of the therapeutic effect. As described in the previous chapter, coupling of various analytic tools in this way can allow for a more complete assessment of a therapeutic activity, a biomedical device's success, or a combination therapy's clinical benefit where a drug coating may be delivered to a targeted area using a biomedical device as a delivery system (e.g., drug eluting stents). The therapeutic evaluated in the current study was a topical dissolved oxygen dressing (OxygeneSys™ Continuous, AcryMed, Inc., Beaverton, OR). Clinical evaluations demonstrated that the dressing was well tolerated and several measures of skin health and integrity showed improvements compared to a control dressing site. Quantitative data from histology, immunohistochemistry, and gene expression studies demonstrated a general reduction in inflammatory response markers and transcription products (IL-6, IL-8, TNF-alpha, MMP-1, and MMP-12) while facilitating a general increase in structural skin proteins (collagen I, elastin, and filaggrin). Additionally, p53 signals from biopsy samples support the conclusion that the topical therapeutic presented no safety concerns. In summary, the data from this study demonstrated that the dressing had no deleterious effects and stimulated beneficial effects on intact, nonwounded skin. Additionally, quantitative histomorphometry and quantitative polymerase chain reaction (PCR) techniques provided unique tools to comprehensively assess clinical benefits.

Original languageEnglish (US)
Title of host publicationMolecular Histopathology and Tissue Biomarkers in Drug and Diagnostic Development
PublisherSpringer New York
Pages163-174
Number of pages12
ISBN (Electronic)9781493926817
ISBN (Print)9781493926800
DOIs
StatePublished - Jun 15 2015

Fingerprint

Bandages
Polymerase Chain Reaction
Skin
Matrix Metalloproteinases
Immunohistochemistry
Therapeutics
Gene Expression
Equipment and Supplies
Drug-Eluting Stents
Elastin
Health
Therapeutic Uses
Interleukin-8
Interleukin-6
Histology
Healthy Volunteers
Collagen
Tumor Necrosis Factor-alpha
Oxygen
Biopsy

Keywords

  • Gene expression
  • Histology
  • Immunohistochemistry
  • Product development
  • qPCR
  • Quantitative histomorphometry
  • Quantitative polymerase chain reaction
  • RT-PCR

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Audet, R. G., Diller, R. B., & Kellar, R. S. (2015). Quantitative histomorphometry and quantitative polymerase chain reaction (PCR) as assessment tools for product development. In Molecular Histopathology and Tissue Biomarkers in Drug and Diagnostic Development (pp. 163-174). Springer New York. https://doi.org/10.1007/7653_2014_38

Quantitative histomorphometry and quantitative polymerase chain reaction (PCR) as assessment tools for product development. / Audet, Robert G.; Diller, Robert B.; Kellar, Robert S.

Molecular Histopathology and Tissue Biomarkers in Drug and Diagnostic Development. Springer New York, 2015. p. 163-174.

Research output: Chapter in Book/Report/Conference proceedingChapter

Audet, RG, Diller, RB & Kellar, RS 2015, Quantitative histomorphometry and quantitative polymerase chain reaction (PCR) as assessment tools for product development. in Molecular Histopathology and Tissue Biomarkers in Drug and Diagnostic Development. Springer New York, pp. 163-174. https://doi.org/10.1007/7653_2014_38
Audet RG, Diller RB, Kellar RS. Quantitative histomorphometry and quantitative polymerase chain reaction (PCR) as assessment tools for product development. In Molecular Histopathology and Tissue Biomarkers in Drug and Diagnostic Development. Springer New York. 2015. p. 163-174 https://doi.org/10.1007/7653_2014_38
Audet, Robert G. ; Diller, Robert B. ; Kellar, Robert S. / Quantitative histomorphometry and quantitative polymerase chain reaction (PCR) as assessment tools for product development. Molecular Histopathology and Tissue Biomarkers in Drug and Diagnostic Development. Springer New York, 2015. pp. 163-174
@inbook{d9f8b95509e54a06b1414a2c30f71a82,
title = "Quantitative histomorphometry and quantitative polymerase chain reaction (PCR) as assessment tools for product development",
abstract = "In the current chapter, 12 normal, healthy subjects were enrolled in a clinical study to assess the efficacy of a topically delivered therapeutic to improve the health and appearance of skin. Clinical and histological assessments along with immunohistochemistry and gene expression results were evaluated using quantitative methods for a comprehensive determination of the therapeutic effect. As described in the previous chapter, coupling of various analytic tools in this way can allow for a more complete assessment of a therapeutic activity, a biomedical device's success, or a combination therapy's clinical benefit where a drug coating may be delivered to a targeted area using a biomedical device as a delivery system (e.g., drug eluting stents). The therapeutic evaluated in the current study was a topical dissolved oxygen dressing (OxygeneSys™ Continuous, AcryMed, Inc., Beaverton, OR). Clinical evaluations demonstrated that the dressing was well tolerated and several measures of skin health and integrity showed improvements compared to a control dressing site. Quantitative data from histology, immunohistochemistry, and gene expression studies demonstrated a general reduction in inflammatory response markers and transcription products (IL-6, IL-8, TNF-alpha, MMP-1, and MMP-12) while facilitating a general increase in structural skin proteins (collagen I, elastin, and filaggrin). Additionally, p53 signals from biopsy samples support the conclusion that the topical therapeutic presented no safety concerns. In summary, the data from this study demonstrated that the dressing had no deleterious effects and stimulated beneficial effects on intact, nonwounded skin. Additionally, quantitative histomorphometry and quantitative polymerase chain reaction (PCR) techniques provided unique tools to comprehensively assess clinical benefits.",
keywords = "Gene expression, Histology, Immunohistochemistry, Product development, qPCR, Quantitative histomorphometry, Quantitative polymerase chain reaction, RT-PCR",
author = "Audet, {Robert G.} and Diller, {Robert B.} and Kellar, {Robert S}",
year = "2015",
month = "6",
day = "15",
doi = "10.1007/7653_2014_38",
language = "English (US)",
isbn = "9781493926800",
pages = "163--174",
booktitle = "Molecular Histopathology and Tissue Biomarkers in Drug and Diagnostic Development",
publisher = "Springer New York",
address = "United States",

}

TY - CHAP

T1 - Quantitative histomorphometry and quantitative polymerase chain reaction (PCR) as assessment tools for product development

AU - Audet, Robert G.

AU - Diller, Robert B.

AU - Kellar, Robert S

PY - 2015/6/15

Y1 - 2015/6/15

N2 - In the current chapter, 12 normal, healthy subjects were enrolled in a clinical study to assess the efficacy of a topically delivered therapeutic to improve the health and appearance of skin. Clinical and histological assessments along with immunohistochemistry and gene expression results were evaluated using quantitative methods for a comprehensive determination of the therapeutic effect. As described in the previous chapter, coupling of various analytic tools in this way can allow for a more complete assessment of a therapeutic activity, a biomedical device's success, or a combination therapy's clinical benefit where a drug coating may be delivered to a targeted area using a biomedical device as a delivery system (e.g., drug eluting stents). The therapeutic evaluated in the current study was a topical dissolved oxygen dressing (OxygeneSys™ Continuous, AcryMed, Inc., Beaverton, OR). Clinical evaluations demonstrated that the dressing was well tolerated and several measures of skin health and integrity showed improvements compared to a control dressing site. Quantitative data from histology, immunohistochemistry, and gene expression studies demonstrated a general reduction in inflammatory response markers and transcription products (IL-6, IL-8, TNF-alpha, MMP-1, and MMP-12) while facilitating a general increase in structural skin proteins (collagen I, elastin, and filaggrin). Additionally, p53 signals from biopsy samples support the conclusion that the topical therapeutic presented no safety concerns. In summary, the data from this study demonstrated that the dressing had no deleterious effects and stimulated beneficial effects on intact, nonwounded skin. Additionally, quantitative histomorphometry and quantitative polymerase chain reaction (PCR) techniques provided unique tools to comprehensively assess clinical benefits.

AB - In the current chapter, 12 normal, healthy subjects were enrolled in a clinical study to assess the efficacy of a topically delivered therapeutic to improve the health and appearance of skin. Clinical and histological assessments along with immunohistochemistry and gene expression results were evaluated using quantitative methods for a comprehensive determination of the therapeutic effect. As described in the previous chapter, coupling of various analytic tools in this way can allow for a more complete assessment of a therapeutic activity, a biomedical device's success, or a combination therapy's clinical benefit where a drug coating may be delivered to a targeted area using a biomedical device as a delivery system (e.g., drug eluting stents). The therapeutic evaluated in the current study was a topical dissolved oxygen dressing (OxygeneSys™ Continuous, AcryMed, Inc., Beaverton, OR). Clinical evaluations demonstrated that the dressing was well tolerated and several measures of skin health and integrity showed improvements compared to a control dressing site. Quantitative data from histology, immunohistochemistry, and gene expression studies demonstrated a general reduction in inflammatory response markers and transcription products (IL-6, IL-8, TNF-alpha, MMP-1, and MMP-12) while facilitating a general increase in structural skin proteins (collagen I, elastin, and filaggrin). Additionally, p53 signals from biopsy samples support the conclusion that the topical therapeutic presented no safety concerns. In summary, the data from this study demonstrated that the dressing had no deleterious effects and stimulated beneficial effects on intact, nonwounded skin. Additionally, quantitative histomorphometry and quantitative polymerase chain reaction (PCR) techniques provided unique tools to comprehensively assess clinical benefits.

KW - Gene expression

KW - Histology

KW - Immunohistochemistry

KW - Product development

KW - qPCR

KW - Quantitative histomorphometry

KW - Quantitative polymerase chain reaction

KW - RT-PCR

UR - http://www.scopus.com/inward/record.url?scp=85026217533&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026217533&partnerID=8YFLogxK

U2 - 10.1007/7653_2014_38

DO - 10.1007/7653_2014_38

M3 - Chapter

AN - SCOPUS:85026217533

SN - 9781493926800

SP - 163

EP - 174

BT - Molecular Histopathology and Tissue Biomarkers in Drug and Diagnostic Development

PB - Springer New York

ER -